Trial Profile
A phase I/II trial to investigate the efficacy, safety and tolerability of the nasal influenza vaccine in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 Jan 2016
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Proof of concept
- 12 Jan 2016 New trial record
- 18 May 2010 Results published in an Eurocine Vaccines media release.